{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T17:14:34Z","timestamp":1778087674438,"version":"3.51.4"},"reference-count":77,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1053\/j.ajkd.2025.10.022","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:55:36Z","timestamp":1772643336000},"page":"730-739","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology"],"prefix":"10.1053","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4258-1726","authenticated-orcid":false,"given":"Amy K.","family":"Mottl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre L.","family":"Sawinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petter","family":"Bjornstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1053\/j.ajkd.2025.10.022_bib1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.022_bib2","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1111\/dom.15185","article-title":"All-cause mortality and cardiovascular outcomes with sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes","volume":"25","author":"Riley","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.022_bib3","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.022_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/MNH.0000000000000844","article-title":"The changing trajectory of diabetic kidney disease","volume":"32","author":"Mistry","year":"2023","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.022_bib5","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"10.1053\/j.ajkd.2025.10.022_bib6","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMoa2205225","article-title":"Multicenter, randomized trial of a bionic pancreas in type 1 diabetes","volume":"387","author":"Russell","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1053\/j.ajkd.2025.10.022_bib7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes","volume":"381","author":"Brown","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2025.10.022_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9169296","article-title":"Insulin-induced lipohypertrophy in patients with type 1 diabetes mellitus treated with an insulin pump","volume":"2022","author":"Ucieklak","year":"2022","journal-title":"Int J Endocrinol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.022_bib9","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.2337\/dc16-0610","article-title":"Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control","volume":"39","author":"Famulla","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.022_bib10","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2337\/dc24-0335","article-title":"Prevalence of chronic kidney disease in type 1 diabetes among adults in the U.S","volume":"47","author":"Rossing","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.022_bib11","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2337\/dc17-1118","article-title":"Cumulative kidney complication risk by 50 years of type 1 diabetes: the effects of sex, age, and calendar year at onset","volume":"41","author":"Costacou","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.022_bib12","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.2337\/dc16-1162","article-title":"A contemporary estimate of total mortality and cardiovascular disease risk in young adults with type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications Study","volume":"39","author":"Miller","year":"2016","journal-title":"Diabetes Care"},{"issue":"16","key":"10.1053\/j.ajkd.2025.10.022_bib13","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.116.025961","article-title":"Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus","volume":"135","author":"Rawshani","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.022_bib14","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S2213-8587(21)00172-8","article-title":"Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study","volume":"9","author":"Harjutsalo","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.022_bib15","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1681\/ASN.V1191667","article-title":"Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease","volume":"11","author":"White","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.022_bib16","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s001250050616","article-title":"Patterns of renal injury in NIDDM patients with microalbuminuria","volume":"39","author":"Fioretto","year":"1996","journal-title":"Diabetologia"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.022_bib17","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.022_bib18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/M22-3078","article-title":"Prevalence and management of obesity in U.S. adults with type 1 diabetes","volume":"176","author":"Fang","year":"2023","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.022_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/dom.14248","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52-week outcomes from the DEPICT-1 and -2 studies","volume":"23","author":"Phillip","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.022_bib20","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.022_bib21","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 Study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.022_bib22","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 Study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1053\/j.ajkd.2025.10.022_bib23","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.022_bib24","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1053\/j.ajkd.2025.10.022_bib25","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/dia.2019.0157","article-title":"Sotagliflozin added to optimized insulin therapy leads to lower rates of clinically relevant hypoglycemic events at any HbA1c at 52 weeks in adults with type 1 diabetes","volume":"21","author":"Danne","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.022_bib26","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.07700621","article-title":"Kidney effects of empagliflozin in people with type 1 diabetes","volume":"16","author":"Cherney","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.022_bib27","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"Van Raalte","year":"2019","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.022_bib28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","article-title":"Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials","volume":"8","author":"Groop","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.022_bib29","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s13300-023-01523-0","article-title":"The effect of sodium-glucose cotransporter inhibitors on renal function as adjunctive to insulin in adults with type 1 diabetes: an updated multilevel meta-analysis of randomized controlled trials","volume":"15","author":"Karakasis","year":"2024","journal-title":"Diabetes Ther"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.022_bib30","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/dom.15047","article-title":"Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes","volume":"25","author":"Stougaard","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"10365","key":"10.1053\/j.ajkd.2025.10.022_bib32","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.022_bib79","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.35792","article-title":"Comparison of diabetes medications used by adults with commercial insurance vs medicare advantage, 2016 to 2019","volume":"4","author":"McCoy","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.022_bib36","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2337\/dc18-2316","article-title":"International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors","volume":"42","author":"Danne","year":"2019","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1053\/j.ajkd.2025.10.022_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2024-098457","volume":"15","author":"Ngan","year":"2025","journal-title":"BMJ Open"},{"key":"10.1053\/j.ajkd.2025.10.022_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/20420188231180987","article-title":"Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment","volume":"14","author":"Edwards","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.022_bib38","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.022_bib39","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1053\/j.ajkd.2025.10.022_bib40","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/dom.14532","article-title":"Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials","volume":"23","author":"Dejgaard","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.022_bib41","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa149","article-title":"Randomized 52-week phase 2 trial of albiglutide versus placebo in adult patients with newly diagnosed type 1 diabetes","volume":"105","author":"Pozzilli","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2025.10.022_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110908","article-title":"Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: the FINE-ONE trial","volume":"204","author":"Heerspink","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"10S","key":"10.1053\/j.ajkd.2025.10.022_bib78","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2025y0p1zsmv","article-title":"Finerenone in CKD and Type 1 diabetes","volume":"36","author":"Heerspink","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1053\/j.ajkd.2025.10.022_bib44","article-title":"A review on latent autoimmune diabetes in adults","volume":"15","author":"Ravikumar","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.022_bib46","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1210\/clinem\/dgaa710","article-title":"Approach to the patient with MODY-monogenic diabetes","volume":"106","author":"Broome","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1053\/j.ajkd.2025.10.022_bib47","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3390\/jpm12111762","article-title":"Maturity-onset diabetes of the young: mutations, physiological consequences, and treatment options","volume":"12","author":"Younis","year":"2022","journal-title":"J Pers Med"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.022_bib48","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/dom.16048","article-title":"Increased cardiovascular risk in people with LADA in comparison to type 1 diabetes and type 2 diabetes: findings from the DPV registry in Germany and Austria","volume":"27","author":"Golomb","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1053\/j.ajkd.2025.10.022_bib49","series-title":"Diabetes in America","article-title":"Monogenic forms of diabetes","author":"Salguero","year":"2023"},{"key":"10.1053\/j.ajkd.2025.10.022_bib50","article-title":"Advancing monogenic diabetes research and clinical care by creating a data commons: the Precision Diabetes Consortium (PREDICT)","author":"McCullough","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2025.10.022_bib51","doi-asserted-by":"crossref","first-page":"i24","DOI":"10.1093\/ndt\/gfz228","article-title":"Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes","volume":"35","author":"Van Raalte DH","year":"2020","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.022_bib52","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5603\/cd.99034","article-title":"SGLT2 inhibitor significantly improved plasma glucose levels in a patient with latent autoimmune diabetes of adults: a case report","volume":"13","author":"Okada","year":"2024","journal-title":"Clin Diabetol"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.022_bib53","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s42000-025-00632-8","article-title":"Efficacy and safety of SGLT2 inhibitors in the treatment of maturity-onset diabetes of the young (MODY): a case report and literature review","volume":"24","author":"Bombonato","year":"2025","journal-title":"Hormones (Athens)"},{"key":"10.1053\/j.ajkd.2025.10.022_bib54","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.022_bib55","doi-asserted-by":"crossref","first-page":"e962","DOI":"10.1210\/clinem\/dgae372","article-title":"Improved HbA1c and body weight in GADA-positive individuals treated with tirzepatide: a post hoc analysis of SURPASS","volume":"110","author":"Peters","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.022_bib56","article-title":"Semaglutide treatment in adult-onset autoimmune diabetes: a case study with long-term follow-up and periodic evaluation of beta-cell function","volume":"16","author":"Da Porto","year":"2024","journal-title":"Cureus"},{"key":"10.1053\/j.ajkd.2025.10.022_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"39","key":"10.1053\/j.ajkd.2025.10.022_bib58","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000039799","article-title":"GLP-1 receptor agonist-induced diabetic ketoacidosis: a case report","volume":"103","author":"Zhang","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.022_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.70173","article-title":"Maturity-onset diabetes of the young (MODY) with HNF1B p.Glu105Lys mutation achieving significant insulin reduction on tirzepatide: a case report","volume":"13","author":"Sue","year":"2025","journal-title":"Clin Case Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.022_bib60","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3803\/EnM.2022.1629","article-title":"Renal protection of mineralocorticoid receptor antagonist, finerenone, in diabetic kidney disease","volume":"38","author":"Kim","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"key":"10.1053\/j.ajkd.2025.10.022_bib63","article-title":"Cystic fibrosis-related diabetes: prevalence, screening, and diagnosis","volume":"27","author":"Khare","year":"2022","journal-title":"J Clin Transl Endocrinol"},{"issue":"42","key":"10.1053\/j.ajkd.2025.10.022_bib64","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.3748\/wjg.v19.i42.7276","article-title":"Diagnosis and treatment of diabetes mellitus in chronic pancreatitis","volume":"19","author":"Ewald","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.ajkd.2025.10.022_bib65","article-title":"Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: a cases series and literature review","volume":"38","author":"Ahmed","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.022_bib66","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J Clin Med"},{"issue":"2-suppl 1","key":"10.1053\/j.ajkd.2025.10.022_bib67","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.ajt.2025.01.020","article-title":"OPTN\/SRTR 2023 annual data report: kidney","volume":"25","author":"Lentine","year":"2025","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2025.10.022_bib68","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1681\/ASN.2021111517","article-title":"Premature death in kidney transplant recipients: the time for trials is now","volume":"33","author":"Vinson","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.022_bib69","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/j.ajkd.2016.08.018","article-title":"Renin-angiotensin system blockade and long-term clinical outcomes in kidney transplant recipients: a meta-analysis of randomized controlled trials","volume":"69","author":"Hiremath","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2025.10.022_bib70","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3390\/jcm14020651","article-title":"Utilization trends of glucose-lowering medications among adult kidney transplant recipients with type 2 diabetes in the United States","volume":"14","author":"Hansrivijit","year":"2025","journal-title":"J Clin Med"},{"issue":"20","key":"10.1053\/j.ajkd.2025.10.022_bib71","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.3390\/jcm13206181","article-title":"Safety and efficacy of sodium-glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney transplant recipients: synthesis of evidence","volume":"13","author":"Bellos","year":"2024","journal-title":"J Clin Med"},{"issue":"3","key":"10.1053\/j.ajkd.2025.10.022_bib72","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with diabetes mellitus","volume":"51","author":"Diker Cohen","year":"2025","journal-title":"Diabetes Metab"},{"issue":"8","key":"10.1053\/j.ajkd.2025.10.022_bib73","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.ekir.2024.05.022","article-title":"Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: a multicenter propensity score matched study","volume":"9","author":"Lim","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.022_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients","volume":"15","author":"Sheu","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.022_bib75","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1097\/TP.0000000000004945","article-title":"Glucagon-like peptide 1 receptor agonists and cardiovascular outcomes in solid organ transplant recipients with diabetes mellitus","volume":"108","author":"Dotan","year":"2024","journal-title":"Transplantation"},{"issue":"24","key":"10.1053\/j.ajkd.2025.10.022_bib76","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2025.10.022_bib43","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.2337\/diabetes.54.suppl_2.S68","article-title":"Latent autoimmune diabetes in adults: definition, prevalence, beta-cell function, and treatment","volume":"54","author":"Stenstr\u00f6m","year":"2005","journal-title":"Diabetes"},{"issue":"14","key":"10.1053\/j.ajkd.2025.10.022_bib45","doi-asserted-by":"crossref","first-page":"7553","DOI":"10.3390\/ijms22147553","article-title":"Maturity onset diabetes of the young-new approaches for disease modelling","volume":"22","author":"Skoczek","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1053\/j.ajkd.2025.10.022_bib61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.gtc.2024.08.002","article-title":"Risk factors and mechanisms for diabetes in pancreatitis","volume":"54","author":"Parra Villasmil","year":"2025","journal-title":"Gastroenterol Clin North Am"},{"issue":"6","key":"10.1053\/j.ajkd.2025.10.022_bib62","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4239\/wjd.v11.i6.213","article-title":"Cystic fibrosis-related diabetes: the unmet need","volume":"11","author":"Pozo","year":"2020","journal-title":"World J Diabetes"},{"issue":"7","key":"10.1053\/j.ajkd.2025.10.022_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11892-022-01471-2","article-title":"SGLT2 inhibition in type 1 diabetes with diabetic kidney disease: potential cardiorenal benefits can outweigh preventable risk of diabetic ketoacidosis","volume":"22","author":"Liu","year":"2022","journal-title":"Curr Diab Rep"},{"issue":"19","key":"10.1053\/j.ajkd.2025.10.022_bib34","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/jama.2024.18581","article-title":"GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes","volume":"332","author":"Li","year":"2024","journal-title":"JAMA"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626007286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638626007286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:55:26Z","timestamp":1778086526000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638626007286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":77,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0272638626007286"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.10.022","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney and Cardiovascular Protection in Diabetes: Beyond Diabetes Typology","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2025.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}